Med Tech-related technology assessments from NICE in August 2025

Health Technology Evaluation with the Late Stage Assessment (LSA) approach aims to assess technologies that are in widespread or established use in the NHS to inform commissioning and procurement decisions. LSA evaluates whether incremental technological innovations within a category provide justifiable value for money, addressing the inconsistency in how such advancements are typically recognized and valued.

In August 2025, NICE published three new LSAs and made the following recommendations:

• A full range of Transcatheter heart valves for transcatheter aortic valve implantation (TAVI) to treat aortic stenosis should be available for prescription in the NHS services, allowing healthcare professionals and patients to choose the most suitable option. There is insufficient evidence to justify price differences between different transcatheter heart valves for TAVI, so the least expensive clinically appropriate option that meets the patient's needs should be used. Details of everyone having the procedure should be entered into the UK TAVI registry;
• Bed frames for adults in acute medical or surgical hospital wards should be procured when presenting minimum standard features such as preventing patient migration, adjustable height, ergonomic brakes, and steering assistance. Evidence is insufficient to justify price differences for additional features like scales or alarms, turn assistance, power drive, or connectivity. When selecting among suitable models, the most appropriate option should be considered based on safety, usability, compatibility, lifecycle costs, and sustainability, choosing the least expensive if multiple options meet the criteria;
• Compression products for treating venous leg ulcers should be selected based on clinical appropriateness and patient preferences, justifying price variations between hosiery and bandaging. Access to various options, including compression wraps, ensures individualized care. Ultimately, healthcare professionals and patients should collaborate to choose the most suitable compression treatment, considering its impact on quality of life and daily functioning.

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.